Queensland’s top researchers announce visit to Bio Asia 2025 on biotech, AI-driven healthcare

Hyderabad: Trade and Investment Queensland (TIQ) announced its delegation for Bio Asia 2025 Summit, led by Prof Alan Rowan, director, University of Queensland. The delegation of over 15 leaders from top research institutions, biotech firms and healthcare organizations aims to build strategic partnerships in biotechnology, clinical research, AI-driven healthcare and advanced vaccine development.

Trade and Investment Queensland (TIQ) is the dedicated business agency of the Government of Queensland.

Abhinav Bhatia, senior trade and investment commissioner - South Asia, Trade and Investment Queensland, emphasised the strategic importance of this visit: “BioAsia is a vital platform for global collaboration in life sciences and trade and investment. Queensland is proud to be one of the global sponsors for the second consecutive year. Our participation highlights Queensland’s commitment to advancing biotechnology, fostering research partnerships and driving innovation in healthcare. Last year’s engagement opened doors to meaningful collaborations, and we are excited to build on that momentum, creating new opportunities for investment and scientific exchange between Queensland and India.”

In a statement, Prof Alan Rowan, director and Interim pro vice-chancellor (Research Infrastructure), AIBN, at the University of Queensland said, “Queensland’s presence at BioAsia 2025 represents our commitment to co-develop solutions that address global healthcare challenges. Our research institutions and companies aim to leverage expertise to complement India’s rapidly expanding life sciences ecosystem, to expedite scientific breakthroughs.”

The conference will explore crucial topics including AI transformation in healthcare, innovation in life sciences R&D and strengthening the global bioeconomy. A highlight will be the panel discussion on clinical trials featuring Prof Evelin Tiralongo, director of the Clinical Trial Unit at Griffith University, showcasing Queensland’s advanced capabilities in conducting Phase I-IV clinical trials.

The visit builds on Queensland’s growing engagement with India’s life sciences sector, aiming to create lasting partnerships that drive innovation in healthcare, biotechnology, and life sciences. This collaboration aligns with both region’s commitment to advancing global healthcare solutions through shared expertise and resources.

Through this strategic engagement at BioAsia 2025, Queensland seeks to strengthen its position as a key partner in India's expanding life sciences ecosystem, building relationships that will accelerate scientific advancement and create economic opportunities for both regions.